Literature DB >> 27668047

Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2016        PMID： 27668047      PMCID： PMC5013856     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  7 in total

1.  Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.

Authors:  April Teitelbaum; Abbie Ba-Mancini; Hui Huang; Henry J Henk
Journal:  Oncologist       Date:  2013-01-08

2.  The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.

Authors:  Louis P Garrison; Si-Tien Wang; Hui Huang; Abbie Ba-Mancini; Hongliang Shi; Kristina Chen; Caroline Korves; Ravinder Dhawan; Andrew Cakana; Helgi van de Velde; Deyanira Corzo; Mei Sheng Duh
Journal:  Oncologist       Date:  2013-01-08

Review 3.  Novel approaches to treatment of double-refractory multiple myeloma.

Authors:  Hans C Lee; Jatin J Shah; Robert Z Orlowski
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013

4.  Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

Authors:  Henk M Lokhorst; Torben Plesner; Jacob P Laubach; Hareth Nahi; Peter Gimsing; Markus Hansson; Monique C Minnema; Ulrik Lassen; Jakub Krejcik; Antonio Palumbo; Niels W C J van de Donk; Tahamtan Ahmadi; Imran Khan; Clarissa M Uhlar; Jianping Wang; A Kate Sasser; Nedjad Losic; Steen Lisby; Linda Basse; Nikolai Brun; Paul G Richardson
Journal:  N Engl J Med       Date:  2015-08-26       Impact factor: 91.245

5.  Improved survival in multiple myeloma and the impact of novel therapies.

Authors:  Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

Review 6.  New strategies in the treatment of multiple myeloma.

Authors:  Nikhil C Munshi; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2013-03-20       Impact factor: 12.531

Review 7.  Multiple myeloma: the bone marrow microenvironment and its relation to treatment.

Authors:  S W Andrews; S Kabrah; J E May; C Donaldson; H R Morse
Journal:  Br J Biomed Sci       Date:  2013       Impact factor: 3.829
  7 in total
  6 in total

Review 1.  Nanomedicines in B cell-targeting therapies.

Authors:  Jiawei Wang; Jiyuan Yang; Jindřich Kopeček
Journal:  Acta Biomater       Date:  2021-10-21       Impact factor: 8.947

2.  Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.

Authors:  Prashant Ramesh Tembhare; Harshini Sriram; Twinkle Khanka; Gaurav Chatterjee; Devasis Panda; Sitaram Ghogale; Yajamanam Badrinath; Nilesh Deshpande; Nikhil V Patkar; Gaurav Narula; Bhausaheb Bagal; Hasmukh Jain; Manju Sengar; Navin Khattry; Shripad Banavali; Sumeet Gujral; Papagudi G Subramanian
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

3.  Acute bilateral angle closure induced by monoclonal antibody (Daratumumab) infusion.

Authors:  Aim-On Saengsirinavin; Wisaruta Wutthayakorn; Sunee Chansangpetch; Anita Manassakorn; Visanee Tantisevi; Noppacharn Uaprasert
Journal:  Am J Ophthalmol Case Rep       Date:  2021-03-26

Review 4.  Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias.

Authors:  Kinga Panuciak; Mikołaj Margas; Karolina Makowska; Monika Lejman
Journal:  Cells       Date:  2022-01-02       Impact factor: 6.600

5.  Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction.

Authors:  Manav Gandhi; Viral Bakhai; Jash Trivedi; Adarsh Mishra; Fernando De Andrés; Adrián LLerena; Rohit Sharma; Sujit Nair
Journal:  Transl Oncol       Date:  2022-09-11       Impact factor: 4.803

Review 6.  Epigenetic Mechanisms in Canine Cancer.

Authors:  Pedro Luiz Porfirio Xavier; Susanne Müller; Heidge Fukumasu
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.